Festivals and fairs plan summer comeback
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug could be a blockbuster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Farmers, water agencies brace for drought
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
‘A big change’ on the way as some companies continue remote work
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cal Poly study: Morro Bay wind power could bring thousands of jobs
A wind farm off the coast of Morro Bay could bring 650 jobs and $262 million in annual economic impact to the Central Coast, and an onshore port to assemble and service wind turbines would be a much bigger economic boost, according to a new study by researchers from Cal Poly San Luis Obispo. The Read More →
Semtech shares up after company reports income and revenue growth
Semtech Corp., a Camarillo semiconductor company specializing in Internet of Things applications, saw its income and revenue rise in the first quarter of fiscal year 2021-22, thanks in large part to growth in its wireless and sensing products market. Semtech saw revenue rise 28% year-over-year to $170.4 million, the company said when it released its Read More →
Amgen reaches billion-dollar licensing deal with Japanese firm
Amgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →
